← Eichor
Study identifier: NCT05992532 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

Condition: Gaucher Disease · Acid SphingoMyelinase Deficiency  ·  Sponsor: Fundación Española de Hematología y Hemoterapía

PhaseN/A
Planned participants210
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

The study of splenomegaly, and the follow-up of splenectomized patients, is one of the causes of referral of these patients to pediatric gastroenterology and oncohematology clinics, and adult internal medicine and hematology. The study and management of splenomegaly is well described among the different medical specialties to which these patients arrive. After the application of the different algorithms and the different studies that are carried out, these splenomegaly are identified as being of hepatic, infectious, inflammatory, congestive, hematological origin and primary causes. Despite these studies of splenomegaly, approximately 10-15% of these patients still remain undiagnosed. Several studies have suggested that there is an increased frequency of MGUS (monoclonal gammopathy of undetermined significance) and/or multiple myeloma (MM) among Gaucher patients. Regarding ASMD (Acid Sphingomyelinase Deficiency), few studies have been published but it seems the 21% of patient with ASMD has MGUS and 15% ASMD patients have MGUS. Moreover, patients with MGUS and Gaucher disease (GD) are at increased risk of developing MM. The objective of the present study is to increase the diagnostic sensitivity of these unknown splenomegalys, or unknown splenomegaly patients with MGUS or multiple myeoloma who remain in consultations, using the usual diagnostic clinical procedures of unknown splenomegaly and unknown splenectomy patients, where we include the extraction of a blood sample for d…

This description comes directly from the study's public registry record.

Talk to the study team

FEHH SEHH, MD  ·  91 319 19 98  ·  sehh@sehh.es

Always discuss trial participation with your own doctor first.

Locations (23)

Hospital Universitario de ÁlavaVitoria-Gasteiz, Alava, SpainRecruiting
Hospital Universitario TorrecárdenasAlmería, Almería, SpainRecruiting
Hospital Son EspasesPalma de Mallorca, Balearic Islands, SpainRecruiting
Hospital Parc TaulíSabadell, Barcelona, SpainRecruiting
Hospital Universitario de BurgosBurgos, Burgos, SpainRecruiting
Hospital de ValdepeñasValdepeñas, Ciudad Real, SpainRecruiting
Hospital Universitario Dr. Josep TruetaGirona, Girona, SpainRecruiting
Hospital Universitario Virgen de las NievesGranada, Granada, SpainRecruiting
Hospital San JorgeHuesca, Huesca, SpainRecruiting
Hospital de JaénJaén, Jaén, SpainRecruiting
Hospital del BierzoPonferrada, León, SpainRecruiting
Hospital Arnau de VilanovaLleida, Lleida, SpainRecruiting

+ 11 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05992532